Renal Dosing Master release notes

1,215 clinical records. This release retains all 1,036 records from v7.3, adds 179 records and supplements 56 existing records. It adds selected renal evidence for 237 previously uncovered GlobalRPh RX URLs, with one RX summary and one prescribing-information summary per URL.

Find a renal recommendation

Search the release roundup by product or filter for a dose change, restriction, monitoring, qualified usual dosing, pharmacokinetic finding or evidence gap. Each result identifies the product, renal measure, practical limit and supporting label. Product-specific tables are available for dofetilide, ceftaroline, famciclovir, edoxaban and lamivudine.

For example, the high-clearance warning for edoxaban applies to nonvalvular AF. The famciclovir table is specific to adult herpes zoster. Look for formulation and indication before choosing a row.

Source coverage and open reviews

1,076 of 4,442 recorded RX URLs now have selected content (24.22%). 3,365 known URLs still lack selected content. The retained census lists 666 entries with unresolved destinations and one additional unconfirmed URL.

Both an RX mirror and its underlying label may describe the same evidence. Independent clinical review remains pending. Dated label postings are marked on the affected summaries.

Product-by-product attempt log | Retained source cautions | v7.3 release notes